MA

Mitesh Amrutlal Patel

Director DIN 02785744
DIN 02785744 First appointment Oct 2009
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Oct 2009
Shareholding value β€’β€’β€’β€’ Premium profile

About Mitesh Amrutlal Patel

Data last updated:

Mitesh Amrutlal Patel was a Director at Nahar Pharmaceuticals Private Limited (from 2009) and Director at Swastik Pharmachem Private Limited (from 2011).

DIN 02785744
First Appointment 07 Oct 2009
Oldest Company Age 17 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director07 Oct 20092009Strike Off
Swastik Pharmachem Private Limited U24230GJ2011PTC064873
Director11 Apr 20112011Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Nahar Pharmaceuticals Private Limited
Swastik Pharmachem Private Limited
Premium access

Shareholding and investment profile for Mitesh Amrutlal Patel

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Mitesh Amrutlal Patel

Mitesh Amrutlal Patel was first appointed on 07 Oct 2009 as Director at Nahar Pharmaceuticals Private Limited. The most recent appointment on record is 11 Apr 2011 at Swastik Pharmachem Private Limited.

Mitesh Amrutlal Patel held 2 earlier board appointments: Nahar Pharmaceuticals Private Limited (Director, from 07 Oct 2009); Swastik Pharmachem Private Limited (Director, from 11 Apr 2011).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available